



From Nature for Life

Ad-hoc RELEASE

Announcement according to Article 17 European Market Abuse Regulation (MAR)

Biotest achieves EBIT forecast for 2023

Dreieich, 24 January 2024: According to preliminary and unaudited figures, EBIT improved significantly in the 2023 financial year to € 143 million after € - 16.6 million in the previous year. The EBIT achieved is therefore in the middle of the forecast range of € 130 million and € 170 million.

In the 2023 financial year, the Biotest Group achieved sales of € 684 million after € 516.1 million in the previous year. This includes the share of sales from the technology disclosure and development services with Grifols S.A., as well as one-off effects from the change in the scope of consolidation.

The aforementioned preliminary and unaudited figures for the Biotest Group are calculated in accordance with IFRS.

Biotest will publish the final figures for the 2023 financial year and the annual report on 28 March 2024.

Biotest Aktiengesellschaft
Board of Management

Biotest AG
Landsteinerstr. 5
D-63303 Dreieich
www.biostest.com

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest is a provider of biological therapeutics derived from human plasma. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,400 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest has been part of the Grifols Group, Barcelona, Spain (www.grifols.com).

IR contact

Dr. Monika Baumann (Buttkereit)
phone: +49-6103-801-4406
email: ir@biotest.com

PR contact

Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201

Preference shares: securities' ID No. 522723; ISIN DE0005227235

Listing: Frankfurt (Prime Standard)

Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate